Host-Microbiome Cross-talk in Oral Mucositis

Journal of Dental Research

Volumn 95, Issue 7, 2016, Pages 725-733

  Vasconcelos, R M ^a,b,c   Sanfilippo, N ^a,d   Paster, B J ^e,f   Kerr, A R ^b   Li, Y ^b   Ramalho, L ^c   Queiroz, E L ^b   Smith, B ^a,d   Sonis, S T ^g,h   Corby, P M ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e FORSYTH INSTITUTE   (United States)

^f HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^g Biomodels LLC   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cancer; cancer complications; damage associated molecular pattern; oral microbiome; pathogen associated molecular pattern; Toll like receptor

Indexed keywords

HOST PATHOGEN INTERACTION; HUMAN; MICROBIOLOGY; MICROFLORA; MOUTH; PATHOLOGY; STOMATITIS;

HOST-PATHOGEN INTERACTIONS; HUMANS; MICROBIOTA; MOUTH; STOMATITIS;

EID: 84975456764     PISSN: 00220345     EISSN: 15440591     Source Type: Journal    
DOI: 10.1177/0022034516641890     Document Type: Review

References (52)

1. Ames NJ, Sulima P, Ngo T, Barb J, Munson PJ, Paster BJ, Hart TC,. 2012. A characterization of the oral microbiome in allogeneic stem cell transplant patients. PLoS One. 7 (10): e47628.
2. Andrade ME, Araujo RS, de Barros PA, Soares AD, Abrantes FA, Generoso SV, Fernandes SO, Cardoso VN,. 2015. The role of immunomodulators on intestinal barrier homeostasis in experimental models. Cin Nutr. 34 (6): 1080-1087.
3. Belazi M, Velegraki A, Koussidou-Eremondi T, Andreadis D, Hini S, Arsenis G, Eliopoulou C, Destouni E, Antoniades D., 2004. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol. 19 (6): 347-351.
4. Blijlevens NM, Logan RM, Netea MG,. 2009. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis. J Antimicrob Chemother. 63 (Suppl 1): i36-i40.
5. Carol M, Borruel N, Antolin M, Llopis M, Casellas F, Guarner F, Malagelada JR,. 2006. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J Leukoc Biol. 79 (5): 917-922.
6. Chavan RS, Pannaraj PS, Luna RA, Szabo S, Adesina A, Versalovic J, Krance RA, Kennedy-Nasser AA,. 2013. Significant morbidity and mortality attributable to Rothia mucilaginosa infections in children with hematological malignancies or following hematopoietic stem cell transplantation. Pediatr Hematol Oncol. 30 (5): 445-454.
7. Choi SE, Kim HS,. 2012. Sodium bicarbonate solution versus chlorhexidine mouthwash in oral care of acute leukemia patients undergoing induction chemotherapy: a randomized controlled trial. Asian Nurs Res (Korean Soc Nurs Sci). 6 (2): 60-66.
8. Ciorba MA, Hallemeier CL, Stenson WF, Parikh PJ,. 2015. Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr Opin Support Palliat Care. 9 (2): 157-162.
9. Corby PM, Biesbrock A, Bartizek R, Corby AL, Monteverde R, Ceschin R, Bretz WA,. 2008. Treatment outcomes of dental flossing in twins: molecular analysis of the interproximal microflora. J Periodontol. 79 (8): 1426-1433.
10. de Mendonca RM, de Araujo M, Levy CE, Morari J, Silva RA, Yunes JA, Brandalise SR,. 2012. Prospective evaluation of HSV, Candida spp., and oral bacteria on the severity of oral mucositis in pediatric acute lymphoblastic leukemia. Support Care Cancer. 20 (5): 1101-1107.
11. Elad S, Epstein JB, Raber-Durlacher J, Donnelly P, Strahilevitz J., 2012. The antimicrobial effect of iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. J Oral Pathol Med. 41 (3): 229-234.
12. Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, Tishler RB, Canty TP, Kudrimoti MK, Vera-Llonch M, et al. 2008. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 113 (10): 2704-2713.
13. Eriguchi Y, Takashima S, Oka H, Shimoji S, Nakamura K, Uryu H, Shimoda S, Iwasaki H, Shimono N, Ayabe T, et al. 2012. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting paneth cell production of alpha-defensins. Blood. 120 (1): 223-231.
14. Fujiya M, Musch MW, Nakagawa Y, Hu S, Alverdy J, Kohgo Y, Schneewind O, Jabri B, Chang EB,. 2007. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe. 1 (4): 299-308.
15. Giles FJ, Rodriguez R, Weisdorf D, Wingard JR, Martin PJ, Fleming TR, Goldberg SL, Anaissie EJ, Bolwell BJ, Chao NJ, et al. 2004. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res. 28 (6): 559-565.
16. Holler E, Butzhammer P, Schmid K, Hundsrucker C, Koestler J, Peter K, Zhu W, Sporrer D, Hehlgans T, Kreutz M, et al. 2014. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 20 (5): 640-645.
17. Hu YJ, Shao ZY, Wang Q, Jiang YT, Ma R, Tang ZS, Liu Z, Liang JP, Huang ZW,. 2013. Exploring the dynamic core microbiome of plaque microbiota during head-and-neck radiotherapy using pyrosequencing. PLoS One. 8 (2): e56343.
18. Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, Liu C, West ML, Singer NV, Equinda MJ, et al. 2012. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 209 (5): 903-911.
19. Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A, Nam JH, Rhee JH, Hwang KC, Im SH,. 2010. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A. 107 (5): 2159-2164.
20. Laheij AM, de Soet JJ,. 2014. Can the oral microflora affect oral ulcerative mucositis? Curr Opin Support Palliat Care. 8 (2): 180-187.
21. Laheij AM, de Soet JJ, von dem Borne PA, Kuijper EJ, Kraneveld EA, van Loveren C, Raber-Durlacher JE,. 2012. Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients. Support Care Cancer. 20 (12): 3231-3240.
22. Limaye SA, Haddad RI, Cilli F, Sonis ST, Colevas AD, Brennan MT, Hu KS, Murphy BA,. 2013. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 119 (24): 4268-4276.
23. McGuire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J, Elad S, Gibson F, Oberle-Edwards LK, Bowen J, et al. 2013. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 21 (11): 3165-3177.
24. Napenas JJ, Brennan MT, Coleman S, Kent ML, Noll J, Frenette G, Nussbaum ML, Mougeot JL, Paster BJ, Lockhart PB, et al. 2010. Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 109 (4): 554-560.
25. Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, et al. 2008. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 113 (6): 1446-1452.
26. Pedroso SH, Vieira AT, Bastos RW, Oliveira JS, Cartelle CT, Arantes RM, Soares PM, Generoso SV, Cardoso VN, Teixeira MM, et al. 2015. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology. 161 (10): 1950-1960.
27. Peterson DE,. 1990. Pretreatment strategies for infection prevention in chemotherapy patients. NCI Monogr. 9 (9): 61-71.
28. Peterson DE, Minah GE, Overholser CD, Suzuki JB, DePaola LG, Stansbury DM, Williams LT, Schimpff SC,. 1987. Microbiology of acute periodontal infection in myelosuppressed cancer patients. J Clin Oncol. 5 (9): 1461-1468.
29. Reiff C, Delday M, Rucklidge G, Reid M, Duncan G, Wohlgemuth S, Hormannsperger G, Loh G, Blaut M, Collie-Duguid E, et al. 2009. Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 15 (11): 1721-1736.
30. Reynolds MA, Minah GE, Peterson DE, Weikel DS, Williams LT, Overholser CD, DePaola LG, Suzuki JB,. 1989. Periodontal disease and oral microbial successions during myelosuppressive cancer chemotherapy. J Clin Periodontol. 16 (3): 185-189.
31. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST,. 1998. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 82 (11): 2275-2281.
32. Sharma A, Rath GK, Chaudhary SP, Thakar A, Mohanti BK, Bahadur S., 2012. Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer. 48 (6): 875-881.
33. Sonis ST,. 2004. The pathobiology of mucositis. Nat Rev Cancer. 4 (4): 277-284.
34. Sonis ST,. 2009. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 45 (12): 1015-1020.
35. Sonis ST,. 2010. New thoughts on the initiation of mucositis. Oral Dis. 16 (7): 597-600.
36. Sonis ST,. 2011. Oral mucositis. Anticancer Drugs. 22 (7): 607-612.
37. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB, et al. 2004. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 100 (9 Suppl): 1995-2025.
38. Spijkervet FK, Van Saene HK, Van Saene JJ, Panders AK, Vermey A, Mehta DM, Fidler V., 1991. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol. 46 (3): 167-173.
39. Srikrishna G, Freeze HH,. 2009. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia. 11 (7): 615-628.
40. Stokman MA, Spijkervet FK, Burlage FR, Dijkstra PU, Manson WL, de Vries EG, Roodenburg JL,. 2003. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer. 88 (7): 1012-1016.
41. Stringer AM,. 2013. Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients. 5 (5): 1488-1499.
42. Stringer AM, Logan RM,. 2015. The role of oral flora in the developmentof chemotherapy-induced oral mucositis. J Oral Pathol Med. 44 (2): 81-87.
43. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazale T, Raupach B, Eckert J, Schumann RR, Enders C, Sonnenborn U, et al. 2005. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. 73 (3): 1452-1465.
44. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, Dubin KA, Socci ND, Viale A, et al. 2012. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 55 (7): 905-914.
45. Thomas CM, Versalovic J., 2010. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes. 1 (3): 148-163.
46. Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S, Le Vacon F, de La Cochetiere MF,. 2014. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis-current evidence and potential clinical applications. Aliment Pharmacol Ther. 40 (5): 409-421.
47. van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ,. 2010. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 6 (5): e1000879.
48. Vanhoecke B, De Ryck T, Stringer A, Van de, Wiele T, Keefe D., 2015. Microbiota and their role in the pathogenesis of oral mucositis. Oral Dis. 21 (1): 17-30.
49. Villa A, Sonis ST,. 2015. Mucositis: pathobiology and management. Curr Opin Oncol. 27 (3): 159-164.
50. Wang Y, Zhou X, Xu X., 2013. Oral microbiota: an overlooked etiology for chemotherapy-induced oral mucositis? J Formos Med Assoc. 114 (4): 297-299.
51. Wijers OB, Levendag PC, Harms ER, Gan-Teng AM, Schmitz PI, Hendriks WD, Wilims EB, van der Est H, Visch LL,. 2001. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys. 50 (2): 343-352.
52. Yoneda S, Imai S, Hanada N, Yamazaki T, Senpuku H, Ota Y, Uematsu H., 2007. Effects of oral care on development of oral mucositis and microorganisms in patients with esophageal cancer. Jpn J Infect Dis. 60 (1): 23-28.